Global Bio-chem Technology Group (HKG:0809) expects a net gain (excluding tax effect) of between HK$600 million and HK$800 million for the year 2024, down from HK$4.18 billion a year prior, a Thursday filing with the Hong Kong bourse said.
The biotech firm attributed the lower anticipated net gain mainly to the absence of a one-off gain of roughly HK$4.28 billion on completion of a debt restructuring agreement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。